

## Special Issue

# New Emerging Connections in Tumor Angiogenesis, Lymphangiogenesis and Their Therapeutic Relevance

### Message from the Guest Editors

Research on tumor angiogenesis has led to the discovery of cellular and molecular mediators, therapeutic targets, and the development of anti-angiogenic drugs, some of which reached clinical practice. In contrast to the high expectations based on preclinical results, the clinical benefits of anti-angiogenic therapies have remained modest. Subsequent research has shed new light on the complex cross-talk between the tumor vasculature, metabolism, immune system, tumor adaptation, and escape, and heralded new prospects for new therapeutic opportunities. This Special Issue presents review and original articles reporting on emerging horizons in the field of tumor angiogenesis and lymphangiogenesis, and opportunities for new therapeutic strategies.

### Guest Editors

Prof. Dr. Curzio R. Rüegg

Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland

Dr. Jimmy Stalin

Pathology, Department of Oncology, Microbiology and Immunology, Section of Medicine, Faculty of Science and Medicine, University of Fribourg, Chemin du Musée 18, CH-1700 Fribourg, Switzerland

### Deadline for manuscript submissions

closed (31 January 2022)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/66188](https://mdpi.com/si/66188)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)